|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
6 June 2022 |
|
Main ID: |
NCT03944447 |
|
Date of registration:
|
03/05/2019 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Outcomes Mandate National Integration With Cannabis as Medicine
OMNI-Can |
|
Scientific title:
|
Outcomes Mandate National Integration With Cannabis as Medicine |
|
Date of first enrolment:
|
December 1, 2018 |
|
Target sample size:
|
200000 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT03944447 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Dr. Ryan O Lakin, MD JD |
|
Address:
|
|
|
Telephone:
|
419-214-3220 |
|
Email:
|
ryan.lakin.md@gmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Dr. Ryan O Lakin, MD JD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
OMNI Medical Services Inc |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Clinical diagnosis of a Qualifying Condition for Medical Marijuana
- Must be 18 years or older unless they have consent from their parent or legal guardian
as defined under state law parameters
- Must be willing to complete online surveys at baseline and the follow up points in
this study
Exclusion Criteria:
- Pregnancy
- Breastfeeding
- Inability to provide informed consent
- Inability to complete study visits or questionnaires
- Active suicidality or psychosis, that could be exacerbated by the administration of
cannabis
Age minimum:
7 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Pain
|
|
Corona Virus Infection
|
|
Chronic Pain Due to Injury
|
|
Chronic Traumatic Encephalopathy
|
|
Opioid-use Disorder
|
|
Parkinson Disease
|
|
Chronic Pain Due to Trauma
|
|
Depression
|
|
Autism
|
|
COVID-19
|
|
Multiple Sclerosis
|
|
Bipolar Disorder
|
|
Cancer
|
|
Glaucoma
|
|
Amyotrophic Lateral Sclerosis
|
|
Coronavirus
|
|
Fibromyalgia
|
|
SARS-CoV Infection
|
|
Sickle Cell Disease
|
|
Traumatic Brain Injury
|
|
Ulcerative Colitis
|
|
HIV/AIDS
|
|
Covid19
|
|
Epilepsy
|
|
Seizures
|
|
Anxiety
|
|
Chronic Pain Syndrome
|
|
Crohn Disease
|
|
Hepatitis C
|
|
Inflammatory Bowel Diseases
|
|
Insomnia
|
|
Post Traumatic Stress Disorder
|
|
Tourette Syndrome
|
|
Intervention(s)
|
|
Device: RYAH-Medtech Inhaler
|
|
Drug: Cannabis, Medical
|
|
Primary Outcome(s)
|
|
Treatment of Symptoms
[Time Frame: Five years]
|
|
Prevention of COVID-19
[Time Frame: Five years]
|
|
Treatment of COVID-19
[Time Frame: Five years]
|
|
Secondary Outcome(s)
|
|
Monitoring Adverse Events
[Time Frame: Five years]
|
|
Cannabis Route and Dosing
[Time Frame: Five years]
|
|
Cannabis Impact on Quality of Life
[Time Frame: Five years]
|
|
Secondary ID(s)
|
|
Pro00033337
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|